{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:59:45Z","timestamp":1790859585543,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To externally validate a three-variable Ewing sarcoma score and assess the incremental prognostic value of the Glasgow prognostic score (GPS) in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort included 133 adults treated at 10 Turkish centers (2010\u20132026). The Ewing score used metastases, tumor diameter &amp;gt;5\u00a0cm, and leukocytes &amp;gt;11\u2009000\/mm3; GPS used C-reactive protein &amp;gt;10\u00a0mg\/L and albumin &amp;lt;3.5\u00a0g\/dl. Outcomes were overall (OS) and event-free survival (EFS). Discrimination was assessed using the concordance index and time-dependent area under the curve. Center-clustered Cox models included the Ewing score and ordinal GPS. Bootstrap uncertainty was estimated within centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median 81.1-month follow-up, 67 deaths and 82 EFS events occurred. Ewing score concordance indices were 0.668 (95% bootstrap confidence interval [CI]: 0.613\u20130.721) for OS and 0.688 (95% CI: 0.641\u20130.734) for EFS. High-risk patients had inferior outcomes, but low- and intermediate-risk groups were not separated. Each one-level increase in GPS was associated with shorter OS (hazard ratio [HR]: 2.67, 95% CI: 1.95\u20133.65) and EFS (HR: 2.31, 95% CI: 1.44\u20133.69). GPS increased the concordance index by 0.091 (95% bootstrap CI: 0.041\u20130.143) for OS and 0.070 (95% bootstrap CI: 0.027\u20130.115) for EFS. Its OS association was strongest within 24\u00a0months and attenuated thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Ewing score identified a high-risk population but incompletely separated lower-risk patients. GPS added independent prognostic information, but the extension requires external validation before clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag170","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:26:51Z","timestamp":1789756011000},"source":"Crossref","is-referenced-by-count":0,"title":["External validation of a three-variable Ewing sarcoma prognostic score and incremental value of the Glasgow prognostic score in adults: a multicenter cohort study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-9053","authenticated-orcid":false,"given":"Burak","family":"Pa\u00e7ac\u0131","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Marmara University Faculty of Medicine , Ba\u015f\u0131b\u00fcy\u00fck Yolu Sk. No: 9\/1, Maltepe, 34854 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl","family":"Ak\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bursa Uluda\u011f University Faculty of Medicine , G\u00f6r\u00fckle Kamp\u00fcs\u00fc, \u00dcniversite Cad., Nil\u00fcfer, 16059 Bursa ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Delig\u00f6n\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bursa Uluda\u011f University Faculty of Medicine , G\u00f6r\u00fckle Kamp\u00fcs\u00fc, \u00dcniversite Cad., Nil\u00fcfer, 16059 Bursa ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Jeral","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa , Koca Mustafapa\u015fa Cad. No: 53, Fatih, 34098 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa , Koca Mustafapa\u015fa Cad. No: 53, Fatih, 34098 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"Avc\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital , Olimpiyat Bulvar\u0131 Yolu, Ba\u015fak\u015fehir, 34480 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sakarya University Faculty of Medicine , Korucuk Mah., Konuralp Bulvar\u0131 No: 81\/1, Adapazar\u0131, 54290 Sakarya ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"Hac\u0131bekiro\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sakarya University Faculty of Medicine , Korucuk Mah., Konuralp Bulvar\u0131 No: 81\/1, Adapazar\u0131, 54290 Sakarya ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , D-100 G\u00fcney Yan Yol Cad. No: 47, Cevizli, Kartal, 34865 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odaba\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , D-100 G\u00fcney Yan Yol Cad. No: 47, Cevizli, Kartal, 34865 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Akdo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Medeniyet University , Dumlup\u0131nar Mah., D-100 Karayolu No: 98, Kad\u0131k\u00f6y, 34720 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Be\u015firo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Medeniyet University , Dumlup\u0131nar Mah., D-100 Karayolu No: 98, Kad\u0131k\u00f6y, 34720 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut \u00d6zg\u00fcn","family":"\u00d6zdal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, \u00dcmraniye Training and Research Hospital , Elmal\u0131kent Mah., Adem Yavuz Cad. No: 1, \u00dcmraniye, 34764 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"\u00d6z\u00e7elik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, \u00dcmraniye Training and Research Hospital , Elmal\u0131kent Mah., Adem Yavuz Cad. No: 1, \u00dcmraniye, 34764 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Altay Teke\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University Faculty of Medicine , Emniyet Mah., Mevlana Bulvar\u0131 No: 29, Yenimahalle, 06500 Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"S\u00fctc\u00fco\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gazi University Faculty of Medicine , Emniyet Mah., Mevlana Bulvar\u0131 No: 29, Yenimahalle, 06500 Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif B\u00fc\u015fra","family":"Ayvac\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Bak\u0131rk\u00f6y Dr. Sadi Konuk Training and Research Hospital , Zuhuratbaba Mah., Dr. Tevfik Sa\u011flam Cad. No: 11, Bak\u0131rk\u00f6y, 34147 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Bak\u0131rk\u00f6y Dr. Sadi Konuk Training and Research Hospital , Zuhuratbaba Mah., Dr. Tevfik Sa\u011flam Cad. No: 11, Bak\u0131rk\u00f6y, 34147 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz\u0131m Can","family":"Demircan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Marmara University Faculty of Medicine , Ba\u015f\u0131b\u00fcy\u00fck Yolu Sk. No: 9\/1, Maltepe, 34854 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Sar\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Marmara University Faculty of Medicine , Ba\u015f\u0131b\u00fcy\u00fck Yolu Sk. No: 9\/1, Maltepe, 34854 Istanbul ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100108330945700_ref1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026100108330945700_ref2","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026100108330945700_ref3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"key":"2026100108330945700_ref4","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1200\/JCO.2000.18.17.3108","article-title":"Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group","volume":"18","author":"Cotterill","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026100108330945700_ref5","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1200\/JCO.1998.16.12.3736","article-title":"Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients","volume":"16","author":"Fizazi","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026100108330945700_ref6","first-page":"927","article-title":"Development and validation of a prognostic score at baseline diagnosis for Ewing sarcoma family of tumors: a retrospective single institution analysis of 860 patients","volume":"14","author":"Sasi","year":"2022","journal-title":"Am J Transl Res"},{"key":"2026100108330945700_ref7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"key":"2026100108330945700_ref8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2026100108330945700_ref9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/CMAR.S146827","article-title":"Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma","volume":"9","author":"Li","year":"2017","journal-title":"Cancer Manag Res"},{"key":"2026100108330945700_ref10","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.3390\/cancers14133064","article-title":"The prognostic role of the C-reactive protein and serum lactate dehydrogenase in a pediatric series of bone Ewing sarcoma","volume":"14","author":"Del Baldo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026100108330945700_ref11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.4103\/jcrt.jcrt_1741_21","article-title":"Simple and easily accessible prognostic markers in Ewing sarcoma; neutrophil-lymphocyte ratio, neutrophil-platelet score and systemic-inflammation index","volume":"19","author":"Bal","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"2026100108330945700_ref12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/cancers15051573","article-title":"The prognostic value of the serum level of C-reactive protein for survival of children with Ewing's sarcoma","volume":"15","author":"Errani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026100108330945700_ref13","doi-asserted-by":"publisher","first-page":"8736509","DOI":"10.1155\/2020\/8736509","article-title":"The prognostic role of Glasgow prognostic score and C-reactive protein to albumin ratio for sarcoma: a system review and meta-analysis","volume":"2020","author":"Fang","year":"2020","journal-title":"Dis Markers"},{"key":"2026100108330945700_ref14","doi-asserted-by":"publisher","first-page":"e071018","DOI":"10.1136\/bmj-2022-071018","article-title":"Transparent reporting of multivariable prediction models developed or validated using clustered data: TRIPOD-cluster checklist","volume":"380","author":"Debray","year":"2023","journal-title":"BMJ"},{"key":"2026100108330945700_ref15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2026100108330945700_ref16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2026100108330945700_ref17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2026100108330945700_ref18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4&lt;361::AID-SIM168&gt;3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2026100108330945700_ref19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"2026100108330945700_ref20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"2026100108330945700_ref21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"2026100108330945700_ref22","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026100108330945700_ref23","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026100108330945700_ref24","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.2018.78.2516","article-title":"High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag170\/71559747\/hyag170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag170\/71559747\/hyag170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:33:14Z","timestamp":1790857994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag170\/8859069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag170","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"hyag170"}}